712 related articles for article (PubMed ID: 22409769)
1. Persistence with prescribed antimuscarinic therapy for overactive bladder: a UK experience.
Wagg A; Compion G; Fahey A; Siddiqui E
BJU Int; 2012 Dec; 110(11):1767-74. PubMed ID: 22409769
[TBL] [Abstract][Full Text] [Related]
2. Persistence and Adherence with Mirabegron versus Antimuscarinic Agents in Patients with Overactive Bladder: A Retrospective Observational Study in UK Clinical Practice.
Chapple CR; Nazir J; Hakimi Z; Bowditch S; Fatoye F; Guelfucci F; Khemiri A; Siddiqui E; Wagg A
Eur Urol; 2017 Sep; 72(3):389-399. PubMed ID: 28196724
[TBL] [Abstract][Full Text] [Related]
3. Persistence, adherence, and switch rates among extended-release and immediate-release overactive bladder medications in a regional managed care plan.
D'Souza AO; Smith MJ; Miller LA; Doyle J; Ariely R
J Manag Care Pharm; 2008 Apr; 14(3):291-301. PubMed ID: 18439051
[TBL] [Abstract][Full Text] [Related]
4. The cost-effectiveness of solifenacin vs fesoterodine, oxybutynin immediate-release, propiverine, tolterodine extended-release and tolterodine immediate-release in the treatment of patients with overactive bladder in the UK National Health Service.
Cardozo L; Thorpe A; Warner J; Sidhu M
BJU Int; 2010 Aug; 106(4):506-14. PubMed ID: 20132203
[TBL] [Abstract][Full Text] [Related]
5. Patterns of use of antimuscarinic drugs to treat overactive bladder in Denmark, Sweden, and the United Kingdom.
Margulis AV; Linder M; Arana A; Pottegård A; Berglind IA; Bui CL; Kristiansen NS; Bahmanyar S; McQuay LJ; Atsma WJ; Appenteng K; D'Silva M; Perez-Gutthann S; Hallas J
PLoS One; 2018; 13(9):e0204456. PubMed ID: 30260993
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness analysis of anti-muscarinic agents for the treatment of overactive bladder.
Armstrong EP; Malone DC; Bui CN
J Med Econ; 2012; 15 Suppl 1():35-44. PubMed ID: 22998646
[TBL] [Abstract][Full Text] [Related]
7. A comprehensive non-clinical evaluation of the CNS penetration potential of antimuscarinic agents for the treatment of overactive bladder.
Callegari E; Malhotra B; Bungay PJ; Webster R; Fenner KS; Kempshall S; LaPerle JL; Michel MC; Kay GG
Br J Clin Pharmacol; 2011 Aug; 72(2):235-46. PubMed ID: 21392072
[TBL] [Abstract][Full Text] [Related]
8. [Assessment of prescribing practices in overactive bladder pharmacotherapy across different specialties of India: a prescription trend analysis].
Krunal Vishavadia KV; Sandip Solanki SS; Hiren Prajapati HP; Madhu Sharma MS
Urologiia; 2023 May; (2):66-72. PubMed ID: 37401707
[TBL] [Abstract][Full Text] [Related]
9. Persistence and adherence with mirabegron vs antimuscarinics in overactive bladder: Retrospective analysis of a UK General Practice prescription database.
Wagg AS; Foley S; Peters J; Nazir J; Kool-Houweling L; Scrine L
Int J Clin Pract; 2017 Oct; 71(10):. PubMed ID: 28906080
[TBL] [Abstract][Full Text] [Related]
10. Cost-Effectiveness of Mirabegron Compared with Antimuscarinic Agents for the Treatment of Adults with Overactive Bladder in the United Kingdom.
Nazir J; Maman K; Neine ME; Briquet B; Odeyemi IA; Hakimi Z; Garnham A; Aballéa S
Value Health; 2015 Sep; 18(6):783-90. PubMed ID: 26409605
[TBL] [Abstract][Full Text] [Related]
11. Pharmacoeconomic evaluation of antimuscarinic agents for the treatment of overactive bladder.
Ko Y; Malone DC; Armstrong EP
Pharmacotherapy; 2006 Dec; 26(12):1694-702. PubMed ID: 17125433
[TBL] [Abstract][Full Text] [Related]
12. Antimuscarinic Discontinuation in Patients with Overactive Bladder in Nursing Homes: A Retrospective Study of Medicare Beneficiaries.
Aparasu RR; Sura S; Earla JR; Shiozawa A; Ng DB; Schermer CR
Adv Ther; 2020 Aug; 37(8):3584-3605. PubMed ID: 32638205
[TBL] [Abstract][Full Text] [Related]
13. Which antimuscarinic agents used in the treatment of overactive bladder increase heart rate? a prospective randomized clinical trial.
Cetinel B; Onal B; Gultekin MH; Guzelsoy M; Turegun FA; Dincer M
Int Urol Nephrol; 2019 Mar; 51(3):417-424. PubMed ID: 30725387
[TBL] [Abstract][Full Text] [Related]
14. Antimuscarinic persistence patterns in newly treated patients with overactive bladder: a retrospective comparative analysis.
Sicras-Mainar A; Rejas J; Navarro-Artieda R; Aguado-Jodar A; Ruiz-Torrejón A; Ibáñez-Nolla J; Kvasz M
Int Urogynecol J; 2014 Apr; 25(4):485-92. PubMed ID: 24196653
[TBL] [Abstract][Full Text] [Related]
15. Comparative efficacy and tolerability of solifenacin 5 mg/day versus other oral antimuscarinic agents in overactive bladder: A systematic literature review and network meta-analysis.
Nazir J; Kelleher C; Aballéa S; Maman K; Hakimi Z; Mankowski C; Odeyemi I
Neurourol Urodyn; 2018 Mar; 37(3):986-996. PubMed ID: 29140559
[TBL] [Abstract][Full Text] [Related]
16. Persistence with overactive bladder pharmacotherapy in a Medicaid population.
Shaya FT; Blume S; Gu A; Zyczynski T; Jumadilova Z
Am J Manag Care; 2005 Jul; 11(4 Suppl):S121-9. PubMed ID: 16161385
[TBL] [Abstract][Full Text] [Related]
17. Impact of Overactive Bladder Step Therapy Policies on Medication Utilization and Expenditures Among Treated Medicare Members.
Abbass IM; Caplan EO; Ng DB; Kristy R; Schermer CR; Bradt P; Collins JM; Chan WM; Suehs BT
J Manag Care Spec Pharm; 2017 Jan; 23(1):27-37. PubMed ID: 28025920
[TBL] [Abstract][Full Text] [Related]
18. Effect of Antimuscarinic Drugs on Cognitive Functions in the Management of Overactive Bladder in Elderly.
Rangganata E; Widia F; Rahardjo HE
Acta Med Indones; 2020 Jul; 52(3):255-263. PubMed ID: 33020336
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness analysis of solifenacin versus oxybutynin immediate-release in the treatment of patients with overactive bladder in the United Kingdom.
Hart WM; Abrams P; Munro V; Retsa P; Nazir J
J Med Econ; 2013 Oct; 16(10):1246-54. PubMed ID: 23885660
[TBL] [Abstract][Full Text] [Related]
20. Treatments for overactive bladder: focus on pharmacotherapy.
Geoffrion R;
J Obstet Gynaecol Can; 2012 Nov; 34(11):1092-1101. PubMed ID: 23231848
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]